Effect of Micromixer Design on Lipid Nanocarriers Manufacturing for the Delivery of Proteins and Nucleic Acids.
lipid nanocarriers
lipid nanoparticles
liposomes
manufacture
microfluidics
nucleic acids
proteins
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
07 Apr 2024
07 Apr 2024
Historique:
received:
11
03
2024
revised:
01
04
2024
accepted:
02
04
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
27
4
2024
Statut:
epublish
Résumé
Lipid-based nanocarriers have emerged as helpful tools to deliver sensible biomolecules such as proteins and oligonucleotides. To have a fast and robust microfluidic-based nanoparticle synthesis method, the setup of versatile equipment should allow for the rapid transfer to scale cost-effectively while ensuring tunable, precise and reproducible nanoparticle attributes. The present work aims to assess the effect of different micromixer geometries on the manufacturing of lipid nanocarriers taking into account the influence on the mixing efficiency by changing the fluid-fluid interface and indeed the mass transfer. Since the geometry of the adopted micromixer varies from those already published, a Design of Experiment (DoE) was necessary to identify the operating (total flow, flow rate ratio) and formulation (lipid concentration, lipid molar ratios) parameters affecting the nanocarrier quality. The suitable application of the platform was investigated by producing neutral, stealth and cationic liposomes, using DaunoXome
Identifiants
pubmed: 38675169
pii: pharmaceutics16040507
doi: 10.3390/pharmaceutics16040507
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Regional Operational Programe of the European Regional Development Fund - POR FESR 2014-2020 program - through the project "DSF (Digital Smart Fluidics): Fluidica Digitale per le Scienze della Vita"
ID : 1175234
Organisme : Piano Operativo Salute, F13C22001110001 Traiettoria 4 (T4-CN-02) - Interventi per la creazione di Hub delle Scienze della Vita nei settori della Farmaceutica, del Biomedicale e delle Biotecnologie - Immuno-HUB (Immunoterapia: cura e prevenzione di malatti
ID : F13C22001110001